利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

11 条记录 (耗时 0.032 秒)

    Phenylethylamine derivatives
    1.
    发明授权
    Phenylethylamine derivatives 失效
    苯乙胺衍生物

    公开(公告)号：US06251938B1

    公开(公告)日：2001-06-26

    申请号：US09335555

    申请日：1999-06-18

    申请人： Michael Chorev ,  Tamar Goren ,  Yacov Herzig ,  Jeffrey Sterling ,  Marta Weinstock-Rosin ,  Moussa B. H. Youdim

    发明人： Michael Chorev ,  Tamar Goren ,  Yacov Herzig ,  Jeffrey Sterling ,  Marta Weinstock-Rosin ,  Moussa B. H. Youdim

    IPC分类号： A61K3127

    CPC分类号： C07C271/42 ,  C07C271/56

    摘要： This invention is directed to compounds of the following formula: wherein m is from 0-4; X is O or S; Y is halogeno; R1 is hydrogen or C1-4 alkyl; R2 is hydrogen, C1-4 alkyl or optionally substituted propargyl; and R3 and R4 are each independently hydrogen, C1-8 alkyl, C6-12 aryl, C6-12 cycloalkyl or C6-12 aralkyl, R5 is hydrogen or C1-4 alkyl; and pharmaceutically acceptable salts thereof, provided that when X is O, R2 is optionally substituted propargyl. This invention is also directed to the use of these compounds for treating depression, Attention Deficit Disorder (ADD), Attention Deficit and Hyperactivity Disorder (ADHD), Tourette's Syndrome, Alzheimer's Disease and other dementia's such as senile dementia, dementia of the Parkinson's type, vascular dementia and Lewy body dementia. This invention is further directed to a pharmaceutical composition comprising a therapeutically effective amount of the above-defined compounds and a pharmaceutically acceptable carrier.

    摘要翻译： 本发明涉及下式的化合物：其中m为0-4; X是O或S; Y为卤素; R1是氢或C1-4烷基; R2是氢，C1-4烷基或任选取代的炔丙基; 并且R 3和R 4各自独立地为氢，C 1-8烷基，C 6-12芳基，C 6-12环烷基或C 6-12芳烷基，R 5为氢或C 1-4烷基; 其中X为O时，R2为任选取代的炔丙基。本发明还涉及这些化合物用于治疗抑郁症，注意力缺陷症（ADD），注意力缺陷和多动症（ADHD）的用途， Tourette综合征，阿尔茨海默病和其他痴呆症如老年性痴呆，帕金森氏型痴呆，血管性痴呆和路易体痴呆。本发明还涉及一种药物组合物，其包含治疗有效量的上述化合物和药学上可接受的 载体

    Aminoindan derivatives
    2.
    发明授权
    Aminoindan derivatives 有权
    氨基茚衍生物

    公开(公告)号：US06462222B1

    公开(公告)日：2002-10-08

    申请号：US09944850

    申请日：2001-08-31

    申请人： Michael Chorev ,  Tamar Goren ,  Yacov Herzig ,  Jeffrey Sterling ,  Marta Weinstock-Rosin ,  Moussa B. H. Youdim

    发明人： Michael Chorev ,  Tamar Goren ,  Yacov Herzig ,  Jeffrey Sterling ,  Marta Weinstock-Rosin ,  Moussa B. H. Youdim

    IPC分类号： C07C26100

    CPC分类号： C07C271/56 ,  C07C271/24 ,  C07C271/44 ,  C07C271/58 ,  C07C333/04 ,  C07C2601/14 ,  C07C2602/08 ,  C07C2602/10

    摘要： This invention is directed to compounds of the following formula: wherein when a is 0, b is 1 or 2; when a is 1, b is 1, m is from 0-3, X is 0 or S, Y is halogeno, R1 is hydrogen C1-4 alkyl, R2 is hydrogen, C1-4 alkyl, or optionally substituted propargyl and R1 and R4 are each independently hydrogen, C1-6 alkyl, C6-12 aryl, C6-12 aralkyl each optionally substituted. This invention is also directed to the use of these compounds for treating depression, Attention Deficit Disorder (ADD), Attention Deficit and Hyperactivity Disorder (ADHD), Tourette's Syndrome. Alzheimer's Disease and other dementia's such as senile dementia, dementia of the Parkinson's type, vascular dementia and Lewy body dementia. This invention is further directed to a pharmaceutical composition comprising a therapeutically effective amount of the above-defined compounds and a pharmaceutically acceptable carrier.

    摘要翻译： 本发明涉及下式的化合物：其中当a为0时，b为1或2; 当a为1时，b为1，m为0-3，X为0或S，Y为卤素，R1为氢C1-4烷基，R2为氢，C1-4烷基或任选取代的炔丙基，R1和 R 4各自独立地为氢，C 1-6烷基，C 6-12芳基，各自任选取代的C 6-12芳烷基。本发明还涉及这些化合物用于治疗抑郁症，注意力缺陷（ADD），注意力缺陷和多动症 多动症（ADHD），Tourette综合征。 阿尔茨海默病和其他痴呆症如老年性痴呆，帕金森氏型痴呆，血管性痴呆和路易体痴呆。本发明还涉及包含治疗有效量的上述化合物和药学上可接受的载体的药物组合物。

    Aminoindan derivatives
    3.
    发明授权
    Aminoindan derivatives 有权
    氨基茚衍生物

    公开(公告)号：US06303650B1

    公开(公告)日：2001-10-16

    申请号：US09336493

    申请日：1999-06-18

    申请人： Michael Chorev ,  Tamar Goren ,  Yacov Herzig ,  Jeffrey Sterling ,  Marta Weinstock-Rosin ,  Moussa B. H. Youdim

    发明人： Michael Chorev ,  Tamar Goren ,  Yacov Herzig ,  Jeffrey Sterling ,  Marta Weinstock-Rosin ,  Moussa B. H. Youdim

    IPC分类号： A61K3127

    CPC分类号： C07C271/56 ,  C07C271/24 ,  C07C271/44 ,  C07C271/58 ,  C07C333/04 ,  C07C2601/14 ,  C07C2602/08 ,  C07C2602/10

    摘要： This invention is directed to compounds of the following formula wherein when a is O, b is 1 or 2; when a is 1, b is 1, m is from 0-3 X is O or S, Y is halogeno, R1 is hydrogen C1-4 alkyl, R2 is hydrogen, C1-4 alkyl, or optionally substituted propargyl and R3 and R4 are each independently hydrogen, C1-8 alkyl, C6-12 aryl, C6-12 aralkyl each optionally substituted. This invention is also directed to the use of these compounds for treating depression, Attention Deficit Disorder (ADC), Attention Deficit and Hyperactivity Disorder (ADHD), Tourette's Syndrome, Alzheimer's Disease and other dementia's such as senile dementia, dementia of the Parkinson's type, vascular dementia and Lewy body dementia. This invention is further directed to a pharmaceutical composition comprising a therapeutically effective amount of the above-defined compounds and a pharmaceutically acceptable carrier.

    摘要翻译： 本发明涉及当a是O，b是1或2时，下列化合物的化合物： 当a为1时，b为1，m为0-3 X为O或S，Y为卤素，R1为氢C1-4烷基，R2为氢，C1-4烷基或任选取代的炔丙基，R3和R4 各自独立地为氢，C 1-8烷基，C 6-12芳基，各自任选取代的C 6-12芳烷基。本发明还涉及这些化合物用于治疗抑郁症，注意力缺陷（ADC），注意力缺陷和多动障碍 （ADHD），Tourette综合征，阿尔茨海默氏病和其他痴呆症如老年性痴呆，帕金森氏型痴呆，血管性痴呆和路易体痴呆。本发明还涉及一种药物组合物，其包含治疗有效量的上述定义的化合物 和药学上可接受的载体。

    Aminoindan derivatives
    4.
    再颁专利
    Aminoindan derivatives 有权
    氨基茚衍生物

    公开(公告)号：USRE39616E1

    公开(公告)日：2007-05-08

    申请号：US11091008

    申请日：2005-03-25

    申请人： Michael Chorev ,  Tamar Goren ,  Yacov Herzig ,  Jeffrey Sterling ,  Marta Weinstock-Rosin ,  Moussa B. H. Youdim

    发明人： Michael Chorev ,  Tamar Goren ,  Yacov Herzig ,  Jeffrey Sterling ,  Marta Weinstock-Rosin ,  Moussa B. H. Youdim

    IPC分类号： A61K31/27

    CPC分类号： C07C271/56 ,  C07C271/24 ,  C07C271/44 ,  C07C271/58 ,  C07C333/04 ,  C07C2601/14 ,  C07C2602/08 ,  C07C2602/10

    摘要： This invention is directed to compounds of the following formula: wherein when a is 0, b is 1 or 2; when a is 1, b is 1, m is from 0-3, X is O or S, Y is halogeno, R1 is hydrogen C1-4 alkyl, R2 is hydrogen, C1-4 alkyl, or optionally substituted propargyl and R3 and R4 are each independently hydrogen, C1-6 alkyl, C6-12 aryl, C6-12 aralkyl each optionally substituted. This invention is also directed to the use of these compounds for treating depression, Attention Deficit Disorder (ADD), Attention Deficit and Hyperactivity Disorder (ADHD), Tourette's Syndrome, Alzheimer's Disease and other dementia's such as senile dementia, dementia of the Parkinson's type, vascular dementia and Lewy body dementia.This invention is further directed to a pharmaceutical composition comprising a therapeutically effective amount of the above-defined compounds and a pharmaceutically acceptable carrier.

    摘要翻译： 本发明涉及下式的化合物：其中当a为0时，b为1或2; 当a为1时，b为1，m为0-3，X为O或S，Y为卤素，R 1为氢，C 1-4烷基， R 2是氢，C 1-4烷基或任选取代的炔丙基，R 3和R 4是 各自独立地为氢，C 1-6烷基，C 6-12芳基，C 6-12芳烷基，各自任选取代。 本发明还涉及这些化合物用于治疗抑郁症，注意力缺陷症（ADD），注意力缺陷和多动障碍（ADHD），图雷特氏综合征，阿尔茨海默病和其他痴呆症如老年性痴呆，帕金森氏型痴呆， 血管性痴呆和路易体痴呆。 本发明进一步涉及包含治疗有效量的上述化合物和药学上可接受的载体的药物组合物。

    Aminoindan derivatives
    5.
    发明授权
    Aminoindan derivatives 有权
    氨基茚衍生物

    公开(公告)号：US06538025B2

    公开(公告)日：2003-03-25

    申请号：US09944912

    申请日：2001-08-31

    申请人： Michael Chorev ,  Tamar Goren ,  Yacov Herzig ,  Jeffrey Sterling ,  Marta Weinstock-Rosin ,  Moussa B.H. Youdim

    发明人： Michael Chorev ,  Tamar Goren ,  Yacov Herzig ,  Jeffrey Sterling ,  Marta Weinstock-Rosin ,  Moussa B.H. Youdim

    IPC分类号： A61K3127

    CPC分类号： C07C271/56 ,  C07C271/24 ,  C07C271/44 ,  C07C271/58 ,  C07C333/04 ,  C07C2601/14 ,  C07C2602/08 ,  C07C2602/10

    摘要： This invention is directed to compounds of the following formula: wherein when a is 0, b is 1 or 2; when a is 1, b is 1, m is from 0-3, X is O or S, Y is halogeno, R1 is hydrogen C1-4 alkyl, R2 is hydrogen, C1-4 alkyl, or optionally substituted propargyl and R3 and R4 are each independently hydrogen, C1-6 alkyl, C6-12 aryl, C6-12 aralkyl each optionally substituted. This invention is also directed to the use of these compounds for treating depression, Attention Deficit Disorder (ADD), Attention Deficit and Hyperactivity Disorder (ADHD), Tourette's Syndrome, Alzheimer's Disease and other dementia's such as senile dementia, dementia of the Parkinson's type, vascular dementia and Lewy body dementia. This invention is further directed to a pharmaceutical composition comprising a therapeutically effective amount of the above-defined compounds and a pharmaceutically acceptable carrier.

    摘要翻译： 本发明涉及下式的化合物：其中当a为0时，b为1或2; 当a为1时，b为1，m为0-3，X为O或S，Y为卤素，R1为氢C1-4烷基，R2为氢，C1-4烷基或任选取代的炔丙基，R3和 R 4各自独立地为氢，C 1-6烷基，C 6-12芳基，各自任选取代的C 6-12芳烷基。本发明还涉及这些化合物用于治疗抑郁症，注意力缺陷（ADD），注意力缺陷和多动症 疾病（ADHD），Tourette综合征，阿尔茨海默病和其他痴呆症如老年性痴呆，帕金森氏型痴呆，血管性痴呆和路易体痴呆。本发明还涉及包含治疗有效量的上述定义的药物组合物 化合物和药学上可接受的载体。

    Use of low-dose ladostigil for neuroprotection
    6.
    发明申请
    Use of low-dose ladostigil for neuroprotection 审中-公开

    公开(公告)号：US20070135518A1

    公开(公告)日：2007-06-14

    申请号：US11635922

    申请日：2006-12-08

    申请人： Marta Weinstock-Rosin ,  Shai Shoham

    发明人： Marta Weinstock-Rosin ,  Shai Shoham

    IPC分类号： A61K31/325

    CPC分类号： A61K31/325 ,  A61K31/27

    摘要： The subject invention provides a method of preventing a neurodegenerative disease in a subject or oxidative stress in the brain of a subject, comprising administering to the subject a less than cholinesterase-inhibitory amount or a less than monoamine oxidase-inhibitory amount of R(+)-6-(N-methyl,N-ethyl-carbamoyloxy)-N′-propargyl-1-aminoindan or a salt thereof effective to prevent the neurodegenerative disease or oxidative stress in the subject.

    Ladostigil Therapy For Immunomodulation
    8.
    发明申请
    Ladostigil Therapy For Immunomodulation 有权
    拉托西奇治疗免疫调节

    公开(公告)号：US20140349927A1

    公开(公告)日：2014-11-27

    申请号：US14453187

    申请日：2014-08-06

    申请人： Marta Weinstock-Rosin

    发明人： Marta Weinstock-Rosin

    IPC分类号： A61K31/27 ,  A61K45/06

    CPC分类号： A61K31/27 ,  A61K31/325 ,  A61K45/06 ,  A61K2300/00

    摘要： Methods for treating individuals suffering from inflammation, specifically systemic inflammation including septic shock and inflammatory conditions affecting the gastrointestinal, myocardial and endocrine systems with ladostigil.

    摘要翻译： 用于治疗患有炎症的个体的方法，特别是全身性炎症，包括脓毒性休克和影响胃肠道，心肌和内分泌系统的炎性疾病。

    Use of low-dose ladostigil for neuroprotection
    9.
    发明授权
    Use of low-dose ladostigil for neuroprotection 有权
    使用低剂量的ladostigil进行神经保护

    公开(公告)号：US08420696B2

    公开(公告)日：2013-04-16

    申请号：US11637600

    申请日：2006-12-11

    申请人： Marta Weinstock-Rosin ,  Shai Shoham

    发明人： Marta Weinstock-Rosin ,  Shai Shoham

    IPC分类号： A61K31/27

    CPC分类号： A61K31/27 ,  A61K31/325

    摘要： The subject invention provides a method of preventing a neurodegenerative disease in a subject or oxidative stress in the brain of a subject, comprising administering to the subject a less than cholinesterase-inhibitory amount or a less than monoamine oxidase-inhibitory amount of R(+)-6-(N-methyl,N-ethyl-carbamoyloxy)-N′-propargyl-1-aminoindan or a salt thereof effective to prevent the neurodegenerative disease or oxidative stress in the subject.

    摘要翻译： 本发明提供一种预防受试者的神经变性疾病或受试者脑部氧化应激的方法，其包括对受试者施用少于胆碱酯酶抑制量或少于单胺氧化酶抑制量的R（+） -6-（N-甲基，N-乙基 - 氨基甲酰氧基）-N'-炔丙基-1-氨基茚满或其盐，其有效地防止受试者的神经变性疾病或氧化应激。